Mr. Speaker, I thank our colleague for raising this important issue. He is quite right that the cost of patented medicines in Canada is too high, especially in relation to comparable countries.
That is why, as he also mentioned, we enacted new regulations on July 1, 2022, that will allow us to compare our prices to the prices charged in comparator countries, excluding the U.S. and Switzerland, to make patented medicines more accessible and affordable across Canada in the coming years.